Loading...
Loading...
In a report published Thursday, Jefferies analyst Thomas Wei initiated coverage on
Stemline TherapeuticsSTML with a Buy rating and $60.00 price target.
In the report, Jefferies noted, “STML's lead drug, SL-401, is entering pivotal trials in 2014 in BPDCN, a rare lymphoma, and third-line acute myeloid leukemia. We are impressed by the robust response rates in both settings, including durable complete responses, after a single cycle of treatment, and we believe that even better efficacy could be achieved with multiple SL-401 cycles. We estimate SL-401 peak sales of $500m+.”
Stemline Therapeutics closed on Thursday at $33.88.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in